Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 80 and over Aged. Found 147 abstracts

no pagination
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun;137(3):386-91.   PMCID: 4447525
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 05;373(19):1803-13.
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015 Jan 08;125(2):236-41.   PMCID: PMC4287635
Revenig LM, Canter DJ, Henderson MA, Ogan K, Kooby DA, Maithel SK, Liu Y, Kim S, Master VA. Preoperative quantification of perceptions of surgical frailty. J Surg Res. 2015 Feb;193(2):583-9.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46.
Wang EH, Yu JB, Gross CP, Smaldone MC, Shah ND, Trinh QD, Nguyen PL, Sun M, Han LC, Kim SP. Variation in pelvic lymph node dissection among patients undergoing radical prostatectomy by hospital characteristics and surgical approach: results from the National Cancer Database. J Urol. 2015 Mar;193(3):820-5.
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2014 Aug 21;124(8):1259-65.   PMCID: Pmc4141515
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44.   PMCID: Pmc4229637
Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20;32(12):1210-7.   PMCID: Pmc3986384
Dyer MA, Arvold ND, Chen YH, Pinnell NE, Mitin T, Lee EQ, Hodi FS, Ibrahim N, Weiss SE, Kelly PJ, Floyd SR, Mahadevan A, Alexander BM. The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol. 2014 Jun;9:143.   PMCID: 4132230
Hurwitz MD, Ghanouni P, Kanaev SV, Iozeffi D, Gianfelice D, Fennessy FM, Kuten A, Meyer JE, LeBlang SD, Roberts A, Choi J, Larner JM, Napoli A, Turkevich VG, Inbar Y, Tempany CM, Pfeffer RM. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. J Natl Cancer Inst. 2014 May;106(5).   PMCID: 4112926
Johnson ME, Zhu F, Li T, Wu H, Galloway TJ, Farma JM, Perlis CS, Turaka A. Absolute lymphocyte count: a potential prognostic factor for Merkel cell carcinoma. J Am Acad Dermatol. 2014 Jun;70(6):1028-35.   PMCID: No NIH funding
Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer. 2014 Mar 15;120(6):840-7.   PMCID: Pmc3951722
Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer. 2014 Jul 15;120(14):2114-21.
Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2014 Mar;132(3):526-30.
Pisansky TM, Pugh SL, Greenberg RE, Pervez N, Reed DR, Rosenthal SA, Mowat RB, Raben A, Buyyounouski MK, Kachnic LA, Bruner DW. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. JAMA. 2014 Apr 02;311(13):1300-7.
Raman JD, Lin YK, Kaag M, Atkinson T, Crispen P, Wille M, Smith N, Hockenberry M, Guzzo T, Peyronnet B, Bensalah K, Simhan J, Kutikov A, Cha E, Herman M, Scherr D, Shariat SF, Boorjian SA. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Urol Oncol. 2014 Jan;32(1):47e9-14.
Singla S, Papavasiliou P, Powers B, Gaughan J, von Mehren M, Watson JC, Farma JM. Challenges in the treatment of angiosarcoma: a single institution experience. Am J Surg. 2014 Aug;208(2):254-9.
Arrangoiz R, Papavasiliou P, Singla S, Siripurapu V, Li T, Watson JC, Hoffman JP, Farma JM. Partial stomach-partitioning gastrojejunostomy and the success of this procedure in terms of palliation. Am J Surg. 2013 Sep;206(3):333-9.   PMCID: No NIH funding
Meyer JE, Panico VJ, Marconato HM, Sherr DL, Christos P, Pirog EC. HIV positivity but not HPV/p16 status is associated with higher recurrence rate in anal cancer. J Gastrointest Cancer. 2013 Dec;44(4):450-5.   PMCID: Pmc3963822
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 80 and over Aged

Aged Middle Aged 80 and over Aged Male Adult Female pathology drug therapy therapeutic use mortality adverse effects methods Young Adult Follow-Up Studies Disease-Free Survival Survival Rate Neoplasm Staging radiotherapy Prognosis Local Neoplasm Recurrence Cohort Studies Prostatic Neoplasms Monoclonal Antibodies surgery Kaplan-Meier Estimate Retrospective Studies metabolism Antineoplastic Combined Chemotherapy Protocols administration & dosage Ovarian Neoplasms Head and Neck Neoplasms United States Glandular and Epithelial Neoplasms blood etiology analogs & derivatives Sirolimus Peritoneal Neoplasms Proportional Hazards Models Prospective Studies Neoplasm Invasiveness Postoperative Complications Risk Assessment diagnosis Taxoids Age Factors Prostatectomy chemically induced Brachytherapy Quality of Life Biological Tumor Markers secondary Surgery Treatment Outcome statistics & numerical data Double-Blind Method Factual Databases Combined Modality Therapy Lymphatic Metastasis Skin Neoplasms Neoplasm Proteins Survival Analysis Risk Factors therapy epidemiology genetics Fallopian Tube Neoplasms B-Cell Lymphoma Antineoplastic Agents Neoplasms Sexual Behavior quality of health care Anus Neoplasms Kidney Function Tests Biological Markers skin neoplasm Outcomes Radiation Injuries Melanoma Educational Status Immunoenzyme Techniques Urothelial carcinoma Chemoradiotherapy Frail Elderly Toxicity Ovarian cancer Chemotherapy head and neck cancer Multivariate Analysis Veliparib Rural Population Transitional Cell Carcinoma Glomerular Filtration Rate Breast Neoplasms Superoxide Dismutase High-Volume Hospitals IGF Type 1 Receptor lymph node excision Weight Loss Merkel Cell Carcinoma Patient attitudes treatment outcome use Oxidative Stress Magnetic Resonance Imaging immune function Gastrointestinal Diseases dosage Propionates Pain Registries High-Intensity Focused Ultrasound Ablation Randomized Controlled Trials as Topic Palliative Care Hemangiosarcoma Intensity-Modulated Radiotherapy Medicare Utilization Review biosynthesis Renal-function changes Viral DNA drug effects Prednisone Psychological Adaptation Radiotherapy Dosage Merkel cell carcinoma Brain Neoplasms physiopathology Neoplastic Gene Expression Regulation TOR Serine-Threonine Kinases Phase III Clinical Trials as Topic Nutritional Status Combination Drug Therapy Papillomavirus Infections Deglutition Disorders Kidney Neoplasms baseline weight loss Sulfones Adolescent Survival Case-Control Studies brachytherapy Marriage Neutropenia immunology BRCA2 Genes absolute lymphocyte count Androgen Antagonists Pain Perception Health Insurance
Last updated on Wednesday, April 13, 2016